Serum Concentration of Fentanyl During Conversion From Intravenous to Transdermal Administration to Patients With Chronic Cancer Pain
- 1 June 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Clinical Journal of Pain
- Vol. 29 (6), 487-491
- https://doi.org/10.1097/ajp.0b013e318266f6a5
Abstract
Background: To the best of our knowledge, there have been no reports on the pharmacokinetics and pharmacodynamics during the conversion from continuous intravenous infusion (CII) to transdermal fentanyl administration. The primary objective of the present study was to clarify the pharmacokinetic characteristics during this conversion. A secondary objective was to identify an association between serum albumin and the absorption of fentanyl from the transdermal patch. Methods: A prospective study was conducted from February 2010 to August 2011 that enrolled 19 patients with chronic cancer pain. Patients were classified into 2 study groups according to body mass index and albumin level. All patients received the conversion from CII to transdermal fentanyl using a 2-step taper of CII over 6 hours. Comparisons of efficacy, toxicity, and serum fentanyl concentrations between study groups were analyzed at baseline, 3, 6, 9, 12, 15, 18, and 24 hours after initiation of the conversion. Results: The dose-adjusted serum fentanyl concentrations for all patients were significantly decreased at 15 to 24 hours after conversion compared with baseline, although pain intensity and the number of rescue events remained stable during the conversion. The dose-adjusted serum fentanyl concentrations at 9 to 24 hours were significantly reduced in the low albumin group compared with the normal albumin group (P<0.05). Conclusions: Our study demonstrated that the dose-adjusted serum fentanyl concentrations remained relatively stable, and pain intensity and the number of rescue events remained stable during conversion. Hypoalbuminemia was strongly associated with poor absorption of transdermally administered fentanyl.Keywords
This publication has 13 references indexed in Scilit:
- Transdermal fentanyl matrix patches Matrifen® and Durogesic® DTrans® are bioequivalentEuropean Journal of Pharmaceutics and Biopharmaceutics, 2010
- Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized studySupportive Care in Cancer, 2010
- Transdermal fentanyl in cachectic cancer patientsPain, 2009
- Adverse Effects of Transdermal Opiates Treating Moderate-Severe Cancer Pain in Comparison to Long-Acting Morphine: A Meta-Analysis and Systematic Review of the LiteratureJournal of Palliative Medicine, 2008
- Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulationBritish Journal of Clinical Pharmacology, 2006
- Switching from Reservoir to Matrix Systems for the Transdermal Delivery of Fentanyl: A Prospective, Multicenter Pilot Study in Outpatients with Chronic PainJournal of Pain and Symptom Management, 2005
- The pharmacokinetics of transdermal fentanyl delivered with and without controlled heatThe Journal of Pain, 2003
- A safe and effective method for converting cancer patients from intravenous to transdermal fentanylCancer, 2001
- Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck regionPain, 1997
- Pain measurement in cancer patients: a comparison of six methodsPain, 1994